UTHR vs. NBIX

In the year-to-date period, UTHR achieves a 63.53% return, which is significantly higher than NBIX's 2.78% return. Over the past 10 years, UTHR has underperformed NBIX with an annualized return of 10.72%, while NBIX has yielded a comparatively higher 20.40% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for United Therapeutics Corporation (UTHR) and Neurocrine Biosciences, Inc. (NBIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current UTHR Sharpe Ratio is 2.10, which is higher than the NBIX Sharpe Ratio of 0.38. The chart below compares the historical Sharpe Ratios of UTHR and NBIX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither UTHR nor NBIX has paid dividends to shareholders.

The maximum UTHR drawdown since its inception was -93.18%, roughly equal to the maximum NBIX drawdown of -97.21%. Use the drawdown chart below to compare losses from any high point for UTHR and NBIX. For additional features, visit the drawdowns tool.

United Therapeutics Corporation (UTHR) has a higher volatility of 8.49% compared to Neurocrine Biosciences, Inc. (NBIX) at 6.65%. This indicates that UTHR's price experiences larger fluctuations and is considered to be riskier than NBIX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between United Therapeutics Corporation and Neurocrine Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.